GRMLHIGH SIGNALFINANCIAL10-K

GRML underwent a massive share dilution (325% increase in shares outstanding) while simultaneously achieving dramatic balance sheet improvement through what appears to be a significant equity raise.

The company raised substantial capital that transformed its financial position from distressed to well-capitalized, but at the cost of severe shareholder dilution. The 325% increase in outstanding shares (28.5M to 121.2M) suggests existing shareholders experienced massive dilution, even as the company's cash position improved from $64K to $7.2M and liabilities were nearly eliminated.

Comparing 2026-04-01 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

GRML's balance sheet was dramatically strengthened with cash increasing over 11,000% to $7.2M, total assets growing 290% to $9.6M, and liabilities plummeting 90% to just $130K. However, this improvement came through what appears to be a highly dilutive equity raise, while operating losses deepened significantly from -$2.9M to -$5.9M in operating cash flow and -$6.2M to -$10.6M in net income. The overall picture shows a company that solved its immediate liquidity crisis but at enormous cost to existing shareholders and with worsening operational performance.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+11159%
$64K$7.2M

Cash position surged 11159% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+4521.8%
$158K$7.3M

Current assets grew 4521.8% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+698.4%
$1.2M$9.5M

Equity base grew 698.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+290.4%
$2.5M$9.6M

Asset base grew 290.4% — expansion through organic growth, acquisitions, or capital deployment.

Operating Cash Flow
Cash Flow
-99.9%
-$2.9M-$5.9M

Operating cash flow fell 99.9% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
-93.8%
$1.2M$77K

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-89.8%
$1.3M$130K

Liabilities reduced 89.8% — deleveraging improves balance sheet strength and financial flexibility.

Net Income
P&L
-71.6%
-$6.2M-$10.6M

Net income declined 71.6% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-29%
-$5.5M-$7.1M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-04-01
PRIOR — 2025-03-31
ADDED
Employer Identification No.) 1300 South Boulevard , Unit D Charlotte , NC 28203 (Address of principal executive offices) (Zip Code) (833) 931-6330 (Registrant s telephone number, including area code) Klotho Neurosciences, Inc.
As of March 31, 2026, there were 121,238,660 shares of the registrant s common stock, $0.0001 par value, issued and outstanding.
FORM 10-K SUMMARY 68 SIGNATURES 69 i Introductory Comment Throughout this Annual Report on Form 10-K, the terms we, us, our, our company, Greenland Mines Ltd, Klotho Neurosciences, Inc., the Company and the Registrant refer to Greenland Mines Ltd.
For example, statements regarding our financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as intend, anticipate, believe, estimate, potential(ly), continue, forecast, predict, plan, may, will, could, would, should, expect or the negative of such terms or other comparable terminology.
+7 more — sign up free →
REMOVED
(Exact name of registrant as specified in its charter) Delaware 86-2727441 (State or other jurisdiction of incorporation or organization) (I.R.S.
As of March 31, 2025, there were 28,510,632 shares of the registrant s common stock, $0.0001 par value, issued and outstanding.
FORM 10-K SUMMARY 70 SIGNATURES 71 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Current Report on Form 10-K contains forward-looking statements within the meaning of the federal securities laws regarding, among other things, the plans, strategies, and prospects, both business and financial, of Klotho Neurosciences, Inc.
These statements are based on the beliefs and assumptions of the management of Klotho.
Although Klotho believes that its plans, intentions, and expectations reflected in or suggested by these forward-looking statements are reasonable, Klotho cannot assure you that it will achieve or realize these plans, intentions, or expectations.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →